Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non–Small Cell Lung Cancer. Issue 6 (July 2017)

• Record Type: Journal Article
• Authors: Leonardi, Giulia C.; Oxnard, Geoffrey R.; Haas, Andrea; Lang, Joshua P.; Williams, Jonathan S.; Awad, Mark M.
• Is Part Of: Journal of immunotherapy. Volume 40:Issue 6(2017:Jul./Aug.)
• Publication Date: 2017-07
• Subjects: NSCLC -- immunotherapy -- pembrolizumab -- PD-1 -- autoimmune diabetes; Immunotherapy -- Periodicals; Immunotherapy -- Periodicals; Neoplasms -- therapy -- Periodicals; Electronic journals; Electronic journals; 615.37
• DOI: 10.1097/CJI.0000000000000173
• Languages: English
• ISSNs: 1524-9557

Abstract

Abstract : Programmed cell death protein 1 pathway inhibitors are now routinely administered to patients with non–small cell lung cancer, and prompt recognition of immune-related adverse events is critical to managing serious drug toxicities. Here, we describe a 66-year-old man with no known history of diabetes who presented with diabetic ketoacidosis after receiving 3 doses of pembrolizumab for lung adenocarcinoma. Autoimmune diabetes is a rare but potentially life-threatening complication of programmed cell death protein 1 inhibitors